About 9 results found for searched term "ITD-1" (0.126 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M9243 | ITD-1 | TGF-β Receptor |
| ITD-1 is a selective TGFβ receptor inhibitor with an IC50 of about 0.4-0.8 μM. | ||
| M28689 | NITD-916 | Antibiotic |
| NITD-916, a 4-hydroxy-2-pyridone derivative, is an orally active and highly lipophilic mycobacterial enoyl reductase InhA inhibitor with an IC50 of 570 nM. NITD-916 forms a ternary complex with InhA and NADH to block access to the fatty acyl substrate binding pocket. NITD-916 has potent anti-tuberculosis effects. | ||
| M2571 | GNF-2 | Src-bcr-Abl |
| GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells. | ||
| M13428 | SEL24-B489 | Pim |
| Sel24-b489 is a novel pan-PIM inhibitor that induces apoptosis in DLBCL cell lines at low/submicromol concentrations and has shown activity in xenotransplantation models. It is an effective oral PIM and FLT3-ITD dual inhibitor with Kds of 2, 2 and 3 nM against PIM1, PIM2 and PIM3, respectively. | ||
| M28939 | AC-4-130 | STAT |
| AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML). | ||
| M29420 | HP1328 | FLT3 |
| HP1328 is a potent inhibitor of FLT3 receptor tyrosine kinase (FLT3/ITD mutation). HP1328 is a benzoimidazole scaffold-based compound. HP1328 significantly reduces the leukemia burden and prolongs the survival of mice with FLT3/ITD leukemia. | ||
| M29479 | FLT3/ITD-IN-4 | FLT3 |
| FLT3/ITD-IN-4 (Compound 16) is a selective FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) inhibitor with an IC50 of 2.3 nM. FLT3/ITD-IN-4 can be used for acute myeloid leukemia research. | ||
| M29485 | Tuspetinib | FLT3 |
| HM43239 | ||
| Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC50s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells. | ||
| M40752 | Quizartinib hydrochloride | FLT3 |
| AC220 hydrochloride | ||
| Quizartinib hydrochloride is a FLT3 inhibitor with IC50 values of 1.1 nM for Flt3-ITD and 4.2 nM for Flt3-WT, and is 10-fold more selective for Flt3 than for KIT, PDGFRA, PDGFRB, RET, and CSF-1R. It can be used in studies related to acute myeloid leukemia (AML). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
